MAOB and Alzheimer disease: We also envisaged toincrease their potency and selectivity toward MAO-B by introducinga propargyl amine group, present in many MAO-B inhibitors such asrasagiline, currently approved for treating PD and in phase II clinicaltrials for AD.58 Selection of the trans-configurationfor the linker has been reinforced by recent findings in an analogousfamily of 4-styryl-N-propargylpiperidine derivatives,in which the (E)-isomers were found to selectivelytarget the MAO-B enzyme versus the MAO-A isoform59 (Figure 3).